Thrivent Financial for Lutherans boosted its holdings in HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 33.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 293,624 shares of the company's stock after buying an additional 73,404 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.34% of HealthEquity worth $24,033,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of HealthEquity by 1.7% during the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company's stock worth $715,783,000 after buying an additional 149,133 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its position in HealthEquity by 1.8% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 616,860 shares of the company's stock valued at $53,173,000 after purchasing an additional 11,150 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of HealthEquity by 29.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company's stock valued at $5,535,000 after purchasing an additional 14,573 shares in the last quarter. Diversify Wealth Management LLC bought a new stake in shares of HealthEquity during the second quarter worth about $8,182,000. Finally, GSA Capital Partners LLP acquired a new position in shares of HealthEquity in the third quarter valued at approximately $638,000. Institutional investors own 99.55% of the company's stock.
Several research firms recently commented on HQY. Bank of America boosted their target price on shares of HealthEquity from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. BTIG Research boosted their price objective on shares of HealthEquity from $110.00 to $130.00 and gave the stock a "buy" rating in a research note on Thursday, November 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. JMP Securities reiterated a "market outperform" rating and issued a $105.00 price target on shares of HealthEquity in a research report on Wednesday, September 4th. Finally, Barrington Research restated an "outperform" rating and set a $105.00 price objective on shares of HealthEquity in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $107.23.
Check Out Our Latest Report on HQY
HealthEquity stock opened at $102.67 on Wednesday. The stock has a market capitalization of $8.97 billion, a price-to-earnings ratio of 85.56, a PEG ratio of 1.55 and a beta of 0.52. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $103.12. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. The stock's 50 day moving average price is $86.10 and its two-hundred day moving average price is $81.42.
HealthEquity (NASDAQ:HQY - Get Free Report) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The business had revenue of $299.93 million during the quarter, compared to analysts' expectations of $284.48 million. On average, equities analysts predict that HealthEquity, Inc. will post 2.27 earnings per share for the current year.
In other HealthEquity news, Director Robert W. Selander sold 8,250 shares of the firm's stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now directly owns 54,719 shares of the company's stock, valued at approximately $4,540,582.62. This trade represents a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank Corvino sold 1,247 shares of the business's stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total transaction of $100,084.22. Following the sale, the director now directly owns 4,823 shares of the company's stock, valued at approximately $387,093.98. The trade was a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,536 shares of company stock worth $884,517 in the last three months. Company insiders own 2.20% of the company's stock.
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider HealthEquity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HealthEquity wasn't on the list.
While HealthEquity currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.